Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Rahul Banerjee, Andrew J. Cowan, Marivel Chavez-Ortega, Paul A Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su

Blood (2023) 142 (Supplement 1): 2386.

https://doi.org/10.1182/blood-2023-174554

Published: 2023

Journal Articles

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Kristin Rathje, Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2023-185991

Published: 2023

Journal Articles

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Nico Gagelmann, Anita Badbaran, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger

Blood (2023) 141 (23): 2901–2911.

https://doi.org/10.1182/blood.2023019630

Published: 2023

Includes: Supplemental data

Journal Articles

Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Nico Gagelmann, Anita Badbaran, Markus Ditschkowski, Victoria Panagiota, Bruno Cassinat, Michael Heuser, Felicitas Thol, Christine Wolschke, Rachel B. Salit, Marie Robin, Dietrich W. Beelen, Bart L. Scott, Nicolaus Kroeger

Blood (2021) 138 (Supplement 1): 314.

https://doi.org/10.1182/blood-2021-152712

Published: 2021

Journal Articles

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Elisabetta Xue, MD, Hu Xie, Wendy Leisenring, ScD, Louise E Kimball, PhD RN, Sonia Goyal, Lisa Chung, Rachel Blazevic, Byron Maltez, Ann Dahlberg, MD, Rachel B. Salit, MD, Colleen Delaney, MD MSc, Steven A. Pergam, MDMPH, Michael Boeckh, MD, Filippo Milano, MD PhD, Joshua Aiden Hill, MD

Blood (2019) 134 (Supplement_1): 4556.

https://doi.org/10.1182/blood-2019-124211

Published: 2019

Journal Articles

Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Neel S. Bhatt, Ruta Brazauskas, PhD, Stephanie Bo-Subait, MPH, Rachel B. Salit, MD, Karen Syrjala, PhD, Heather R. Tecca, Minoo Battiwalla, MD, David K. Buchbinder, MD MSHS, Betty K. Hamilton, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD

Blood (2019) 134 (Supplement_1): 706.

https://doi.org/10.1182/blood-2019-124151

Published: 2019

Journal Articles

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Laura Roberts, Rachel B. Salit, MD, Lauren Longo, Elisabetta Xue, MD, Corinne Summers, MD, Colleen Delaney, MD MSc, Ann Dahlberg, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 2048.

https://doi.org/10.1182/blood-2019-126216

Published: 2019

Journal Articles

Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Giancarlo Fatobene, MD, Barry E. Storer, PhD, Rachel B. Salit, MD, Stephanie J. Lee, MD PhD, Paul J. Martin, MD, Guang-Shing Cheng, MD, Colleen Delaney, MD, Frederick R. Appelbaum, MD, Brenda M. Sandmaier, MD, Filippo Milano, MD PhD, Mary E. Flowers, MD

Blood (2017) 130 (Supplement 1): 73.

https://doi.org/10.1182/blood.V130.Suppl_1.73.73

Published: 2017

Journal Articles

Quality of Life of Informal Caregivers of Hematopoietic Cell Transplant Recipients

Kareem Jamani, MD, Lynn E. Onstad, ScM, Rachel B. Salit, MD, Mary E. Flowers, MD, Paul A. Carpenter, MD, Stephanie J. Lee, MD PhD

Blood (2017) 130 (Supplement 1): 280.

https://doi.org/10.1182/blood.V130.Suppl_1.280.280

Published: 2017

Journal Articles

Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies

Alberto Mussetti, MD, Abraham Sebastian Kanate, MD, Mohamed A Kharfan-Dabaja, MD, Kwang Woo Ahn, PhD, Alyssa DiGilio, MS, Stefan O Ciurea, MD, Philippe Armand, MD PhD, Rachel B. Salit, MD, Timothy S. Fenske, MD MS, Sonali M. Smith, MD, Anna Sureda, MD PhD, Javier Bolanos-Meade, MD, Mehdi Hamadani, MD

Blood (2015) 126 (23): 194.

https://doi.org/10.1182/blood.V126.23.194.194

Published: 2015

Journal Articles

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Blood (2015) 126 (23): 65.

https://doi.org/10.1182/blood.V126.23.65.65

Published: 2015

Journal Articles

Comorbidity Index in the Context of Cord Blood Transplantation: An Accurate Predictor of Treatment Related Mortality?

David C. Oliver, Filippo Milano, MD PhD, Colleen Delaney, MD MSC, Mohamed L. Sorror, MD MSc, Rachel B. Salit, MD

Blood (2014) 124 (21): 1205.

https://doi.org/10.1182/blood.V124.21.1205.1205

Published: 2014

Journal Articles

Second Allogeneic Transplant with Cord Blood for Treatment of Failed First Allogeneic Transplant Due to Primary Graft Failure or Disease Recurrence

Rachel B. Salit, MD, Filippo Milano, MD PhD, Ivy B. Riffkin, David C. Oliver, Nancy L. Anderson, Colleen Delaney, MD MSC

Blood (2014) 124 (21): 3940.

https://doi.org/10.1182/blood.V124.21.3940.3940

Published: 2014

Journal Articles

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Rachel B Salit, MD, Filippo Milano, MD, PhD, Jonathan A Gutman, MD, Michael B Maris, MD, Thomas Chauncey, MD, PhD, Finn Petersen, M.D., Colleen Delaney, MD, MSc

Blood (2013) 122 (21): 697.

https://doi.org/10.1182/blood.V122.21.697.697

Published: 2013

Journal Articles

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Brian C. Shaffer, MD, Andrew Flynn, David Moorshead, Zach Powell, Jennifer Hsu, RN, Rachel B Salit, MD, Frances T. Hakim, PhD, Ronald E. Gress, MD, Michael Bishop, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD

Blood (2013) 122 (21): 4580.

https://doi.org/10.1182/blood.V122.21.4580.4580

Published: 2013

Journal Articles

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Rachel B. Salit, MD, Frances T. Hakim, PhD, Michael R. Bishop, MD, Thea M. Friedman, PhD, Robert Korngold, PhD, Kira Goldgirsh, PhD, Sarfraz Memon, MD, Seth M. Steinberg, PhD, David Liewehr, MS, Daniel Peaceman, BS, Jennifer Wilder, RN, Kelly Bryant, RN, Daniel H. Fowler, MD, Juan Gea-Banacloche, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2012) 120 (21): 3054.

https://doi.org/10.1182/blood.V120.21.3054.3054

Published: 2012

Journal Articles

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Rachel B. Salit, MD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Frances T. Hakim, PhD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Kelly Bryant, RN, Jennifer Wilder, RN, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Ronald E. Gress, MD, Daniel H. Fowler, MD

Blood (2011) 118 (21): 1937.

https://doi.org/10.1182/blood.V118.21.1937.1937

Published: 2011

Journal Articles

Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes,

Blood (2011) 118 (21): 4074.

https://doi.org/10.1182/blood.V118.21.4074.4074

Published: 2011

Journal Articles

Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.

Rachel B. Salit, MD, Steven Z. Pavletic, MD, Daniel H. Fowler, MD, Jennifer Wilder, RN, Kelly Bryant, RN, Seth M. Steinberg, PhD, Frances T. Hakim, PhD, Michael R. Bishop, MD

Blood (2010) 116 (21): 1245.

https://doi.org/10.1182/blood.V116.21.1245.1245

Published: 2010

NARROW

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Quality of Life of Informal Caregivers of Hematopoietic Cell Transplant Recipients

Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Comorbidity Index in the Context of Cord Blood Transplantation: An Accurate Predictor of Treatment Related Mortality?

Second Allogeneic Transplant with Cord Blood for Treatment of Failed First Allogeneic Transplant Due to Primary Graft Failure or Disease Recurrence

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes,

Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only